Skip to main content
Back
Watch Compare

NORTHWEST BIOTHERAPEUTICS INC

Data quality: 100%
NWBO
OTC Manufacturing Chemicals
$0.20
▼ $0.00 (-1.58%)
Mkt Cap: 308.14 M
Price
$0.20
Mkt Cap
308.14 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 1.72% annually over 5 years — modest growth
Negative free cash flow of -49.84 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 30.19%

Growth

Revenue Growth (5Y)
1.72%
Below sector avg (1.82%)
Revenue (1Y)-28.47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net Margin-9580.90%
Op. Margin-6927.32%

Safety

Debt / Equity
N/A
Current Ratio0.08
Interest Coverage-7.60

Valuation

PE (TTM)
-3.43
Below sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -3.4 -1.5
P/B — 1.6
ROE % — -53.3
Net Margin % -9580.9 -41.5
Rev Growth 5Y % 1.7 1.8
D/E — 0.3

Analyst Price Target

1 analyst
Strong Buy
Current
$0.20
+402.5%
Target
$1.00
$1.00
$1.00
$1.00
Forecast
Forward P/E -3.98
Forward EPS -$0.05
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2026 -$0.05
-$0.05 – -$0.05
 0.0 1

All Fundamental Metrics
Growth
Revenue Growth (1Y) -28.47% Revenue Growth (3Y) -9.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 1.72% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 937,000.0 Net Income (TTM) -89.77 M
ROE N/A ROA -298.47%
Gross Margin N/A Operating Margin -6927.32%
Net Margin -9580.90% Free Cash Flow (TTM) -49.84 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.08
Interest Coverage -7.60 Asset Turnover 0.03
Working Capital -80.71 M Tangible Book Value -109.27 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.43 Forward P/E N/A
P/B Ratio N/A P/S Ratio 328.85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -16.18%
Market Cap 308.14 M Enterprise Value 375.78 M
Per Share
EPS (Diluted TTM) -0.06 Revenue / Share 0.00
FCF / Share -0.03 OCF / Share -0.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 55.52%
SBC-Adj. FCF N/A Growth Momentum -30.19

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.38 M 1.93 M 1.68 M 1.01 M 1.29 M
Net Income -83.78 M -62.60 M -105.03 M 179.13 M -529.82 M
EPS (Diluted) -0.07 -0.06 -0.10 -0.06 —
Gross Profit — — — — —
Operating Income -66.51 M -55.51 M -67.18 M -52.70 M -86.61 M
EBITDA — — — — —
R&D Expenses 34.89 M 27.73 M 35.51 M 20.31 M 33.64 M
SG&A Expenses — — — — —
D&A 1.74 M 1.53 M 1.25 M 324,000.0 87,000.0
Interest Expense 7.77 M 5.24 M 6.07 M 5.01 M 8.54 M
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 26.73 M 27.87 M 31.32 M 40.16 M 32.90 M
Total Liabilities 105.71 M 74.92 M 136.37 M 164.15 M 395.85 M
Shareholders' Equity -94.49 M -65.77 M -128.10 M -123.99 M -362.95 M
Total Debt 62.68 M 40.79 M 21.59 M 32.46 M 14.84 M
Cash & Equivalents 2.18 M 2.13 M 6.97 M 15.17 M 9.98 M
Current Assets 4.06 M 4.13 M 9.43 M 17.29 M 15.51 M
Current Liabilities 68.27 M 45.20 M 126.01 M 133.77 M 382.42 M